Publications Office of the EU
PL-Gdansk: antineoplastic agents - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates CPV codes deduced from the text of the procedure

- indicates text translated automatically in your browsing language

PL-Gdansk: antineoplastic agents

  • Awarded
    29/11/2010
  • Today
    08/10/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Not available
Place of performance
NUTS code: Not available
Location of buyer
NUTS code: Not available
Business sector (Main CPV)
33652100 Antineoplastic agents
Total estimated contract value (excluding VAT)
422,584.50
Total final contract value (excluding VAT)
1,910,815.09 PLN
Tender reference number
ZP/17/2010
Description

The successive supply of oncological and small medicines to the Provincial Oncology Centre in Gdańsk, broken down into 10 packages, over a period of 12 months.

Submission Method
Not available
Tenders may be submitted
Not applicable
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Not available
CPV code

33652100 - Antineoplastic agents

33690000 - Various medicinal products

Award method
Lowest price
Estimated value
422,584.50
Final contracted value
1,910,815.09 PLN
Award of contract
Not available
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.